As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

As­traZeneca is rolling out the big guns this evening to pro­vide a salute to their ADAU­RA da­ta on Tagris­so at AS­CO.

Can­cer R&D chief José Basel­ga calls the dis­ease-free sur­vival da­ta for their drug in an ad­ju­vant set­ting of ear­ly stage, epi­der­mal growth fac­tor re­cep­tor-mu­tat­ed NSCLC pa­tients fol­low­ing surgery “mo­men­tous.” Roy Herb­st, the prin­ci­pal in­ves­ti­ga­tor out of Yale, calls it “trans­for­ma­tive.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.